Trial Profile
Special Investigation (All Cases Investigation in Patients With Ankylosing Spondylitis)
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 05 Apr 2019
Price :
$35
*
At a glance
- Drugs Adalimumab (Primary)
- Indications Ankylosing spondylitis
- Focus Adverse reactions; Therapeutic Use
- Sponsors Abbott Laboratories; AbbVie
- 24 Jan 2018 Status changed from active, no longer recruiting to completed.
- 03 Aug 2016 Planned End Date changed from 1 May 2018 to 1 Dec 2017.
- 03 Aug 2016 Planned primary completion date changed from 1 Apr 2016 to 1 Dec 2017.